OKYO Pharma
OKYO
5 hedge funds and large institutions have $1.48M invested in OKYO Pharma in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
2.07% more ownership
Funds ownership: 6.12% → 8.19% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less funds holding
Funds holding: 7 → 5 (-2)
44% less capital invested
Capital invested by funds: $2.63M → $1.48M (-$1.16M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$1.27M |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$16.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$195 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34.8K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$25K |
| 3 |
Renaissance Technologies
New York
|
-$17.7K |
| 4 |
CA
Continuum Advisory
Eagle,
Idaho
|
-$64 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DIG
1
Dauntless Investment Group
Etna,
New Hampshire
| $1.39M | +$1.27M | +747,000 | +38% |
|
2
Cerity Partners
New York
| $32.9K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $31.1K | – | – | – |
|
|
4
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| $27.8K | +$16.9K | +10,000 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $296 | +$195 | +115 | New |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$34.8K | -27,404 | Closed |
|
|
FIA
7
FNY Investment Advisers
New York
| – | -$25K | -20,000 | Closed |
|
|
8
Renaissance Technologies
New York
| – | -$17.7K | -13,946 | Closed |
|
|
CA
9
Continuum Advisory
Eagle,
Idaho
| – | -$64 | -50 | Closed |
|
OKYO Hedge Fund Activity: Q2 2025 in Review
5 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2025, worth a combined $1.48M — down 44% from $2.63M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OKYO and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Dauntless Investment Group, adding an estimated $1.27M. The largest seller was Citadel Advisors, exiting entirely with an estimated $34.8K sold.
- 5 institutional investors held OKYO Pharma (OKYO) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $1.48M of OKYO Pharma stock for Q2 2025, down 44% quarter-over-quarter.
- 2 funds opened new OKYO Pharma positions in Q2 2025 and 4 closed out, a net change of -2 holders.
- The largest OKYO Pharma buyer in Q2 2025 was Dauntless Investment Group, an estimated $1.27M added.
- The largest OKYO Pharma seller in Q2 2025 was Citadel Advisors, an estimated $34.8K sold.
Based on aggregated 13F filings for Q2 2025.